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Aims:  The  ESCAPE-NET  project  (“European  Sudden  Cardiac  Arrest  network–  towards  Prevention,  Educa-
tion  and  New  Effective  Treatments”)  aims  to study:  (1)  risk  factors  and  mechanisms  for the  occurrence
of  sudden  cardiac  arrest  (SCA)  in  the  population,  and  (2)  risk  factors  and  treatment  strategies  for  survival
after  SCA  on  a European  scale.
Methods:  This  is an  Horizon2020  funded  program  of  the  European  Union,  performed  by a European  public-
private  consortium  of  16  partners  across  10 EU  countries.  There  are  11  deep-phenotyped  SCA  cohorts  for
the study  of  risk  factors  and  treatment  strategies  for survival  after  SCA,  and  5 deep-phenotyped  obser-
vational  prospective  population  cohorts  for the  study  of  risk  factors  for occurrence  of  SCA.  Personalized
risk  scores  for predicting  SCA  onset  and  for predicting  survival  after  SCA  will  be derived  and  validated.
Results:  The  11 clinical  studies  with  SCA  cases  comprise  85,790  SCA cases;  the  5  observational  prospective
population  cohorts  include  53,060  subjects.  A  total  of  15,000  SCA  samples  will  be  genotyped  for  common
and  rare  variants  at the Helmholtz  Zentrum  München  (Germany)  using  the  Illumina  Global  Screening
Array  which  contains  > 770,000  SNPs,  and after  imputation,  a  database  of  an  estimated  >  9  million  vari-
ants  will  be available  for genome  wide  association  studies.  Standardization  of risk  factors  deﬁnition
and  outcomes  is  ongoing.  An  Executive  Committee  has  been  created  along  with  a  Collaboration  Policy
document.
Conclusion:  ESCAPE-NET  will  
including  the  EuReCa  project.
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Despite recent improvements in cardiopulmonary resuscitation
nd post-resuscitation care, survival after out-of hospital sudden
ardiac arrest (SCA) remains as low as 10% on average when con-
idering the whole spectrum of SCA including SCA with no attempts
f resuscitation by Emergency Medical Services [1]. The challenges
head of us include a better capacity to identify individuals from
he population who are at risk of SCA, improvement in resuscita-
ion strategies, and a better understanding of the mechanisms of
CA.
Multiple studies have reported on individual risk factors for SCA
ccurrence including traditional acquired risk factors or comor-
idities (diabetes, myocardial infarction, hypertension, smoking,
besity) [2], familial predisposition [3] or neural control of heart
hythm [4] (Fig. 1 left). Still, we lack sensitive risk stratiﬁca-
ion algorithms for SCA [5]. Previous attempts at risk prediction
odelling were conducted in speciﬁc subgroups such as patients
ith acute myocardial infarction [6] or, when addressing the
eneral population, considered a limited set of covariates [7].
oreover, while evidence for a role of hitherto little studied risk
actors has recently emerged (socio-economic and psychosocial
tress [8], and environmental factors such as air pollution [9]
nd roadway proximity [10]), the extent to which these emerg-
ng factors contribute to the occurrence of SCA beyond the effect
f already known risk factors remains to be studied. Finally, the
ossible effect of drugs on SCA occurrence and their interaction
ith other risk factors has been insufﬁciently addressed. There
re some reports on the associations between antipsychotics [11]
ith ventricular arrhythmias and/or SCA. However, they are usu-
lly based on a single geographic area or country. Furthermore,
ata on trajectories of exposures to different drugs, taking into
ccount duration and dose, are lacking. Clearly, class and drug
ffects need to be evaluated. Risk stratiﬁcation algorithms based
n ﬁndings from epidemiological studies that evaluate traditional
isk factors, acquired risk factors, environmental risk factors, and
enetic variants in combination may  aid in the identiﬁcation of sus-
eptible individuals and subgroups within the population (Fig. 1
ight).
Improvements in survival after SCA are possible as new treat-
ent strategies for SCA–in particular focusing on early start
f resuscitation procedures–have shown to markedly increase
urvival rates [12–14]. To date, however, there has not been
 large systematic study aimed at comparing the efﬁcacy of
he different treatment protocols across Europe and to establish
hich ﬁrst-response treatment strategy for SCA offers the highest
hance of survival. Importantly, in addition to treatment strate-
ies, patient characteristics and organization of care may  further
mpact on survival, although these factors are poorly considered
imultaneously. This integrative approach has important impli-
ations as it may  help to identify the respective weights of the
eterminants of survival after SCA and to prioritize necessary
mprovements. Also, accounting for differences in patients char-
cteristics, treatment strategies and organization of care may  help
o understand and ultimately reduce the disparities in SCA inci-
ence and survival rates after SCA across Europe and the world
15,16].
To obtain mechanistic insights, studies have focused on dis-
overy of genetic factors on cardiomyopathies and inherited
rrhythmia syndromes, which account for 10–15% of SCA in indus-
rialized societies, and have identiﬁed relevant pathways [17].
or SCA in the general population, only few genetic analyses
ave been conducted so far, mostly because sufﬁciently large
NA collections have been lacking. Most prior studies used a
andidate approach on common variants [18] and so far only 2
enome wide association studies on SCA have been performedtion 124 (2018) 7–13
by members of the ESCAPE-NET consortium [19,20]. In gen-
eral, recognizing risk gene (proﬁles) is of practical importance
in clinical decision making, e.g., when a drug with poten-
tial arrhythmia risk (e.g., QT prolonging cardiac or noncardiac
drugs) must be prescribed to an individual (pharmacogenet-
ics).
Aims
The ESCAPE-NET project (ESCAPE-NET: “European Sudden Car-
diac Arrest network–towards Prevention, Education and New
Effective Treatments”) has two main objectives: (1) to improve our
knowledge of the determinants and mechanisms for the occurrence
of SCA, and (2) to improve our capacities to increase the survival
after SCA on a European scale.
Its speciﬁc aims are:
Towards population cohort integration:
1. To combine Europe’s largest deep-phenotyped SCA cohorts for
full exploitation of the data
2. To improve and maximize data sharing and stimulate
hypothesis-driven research by using new technologies in build-
ing and maintaining this large-scale database
3. To develop a ﬁnancial strategy to keep the database alive after
the duration of the project
4. To reach out to other SCA investigators with interest in collabo-
ration and data sharing
Towards prevention:
1. To identify genetic, epigenetic, acquired, and environmental risk
factors, and their interactions, for SCA occurrence in a combined
large-scale European study population
2. To design a personalized risk score for SCA occurrence
3. To validate the personalized risk score
Towards treatment
1. To relate differences in ﬁrst-response SCA treatment strategies
to survival across different European countries
2. To evaluate effects of novel technologies for SCA treatment by
utilizing smartphone applications (for rapid deployment of lay
rescuers) and novel technological solutions (e.g., based on ven-
tricular ﬁbrillation [VF] waveform analysis)
3. To design a personalized risk score for survival after SCA
The consortium
The ESCAPE-NET project is funded by the Horizon2020 program
of the European Union, and addresses the speciﬁc challenges and
scope of the Horizon2020 call ‘PM04: Networking and optimizing
the use of population and patient cohorts at EU level’. This 5-year
project will be performed by a European public-private consortium
of 16 partners across 10 EU countries (Fig. 2, Table 1), including
academic institutions that provide large patient cohorts, European
scientiﬁc societies/associations for SCA research who  will translate
the outcomes into European clinical practice to prevent SCA and
improve survival after SCA, and small and medium-sized enter-
prises who  contribute speciﬁc expertise. The consortium consists
of Europeans key cardiology and emergency medicine departments
focusing on SCA, together with expert research departments in the
ﬁeld of Public Health, Ethics, Biomedical Informatics, Epidemiology
and Statistics.
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Fig. 1. Risk factors contributing to SCA occurrence (traditional risk factors/comorbidities: DM, diabetes mellitus; MI,  myocardial ischemia/infarction).
Fig. 2. Large differences in survival rates after SCA across Europe. Countries in orange indicate study sites of ESCAPE-NET; the catchment areas in these countries are indicated
in  purple. Numbers indicate survival rates (%) at hospital discharge of patients in whom cardiopulmonary resuscitation was attempted as reported in the EuReCa One Registry
[16] (survival rates in that registry were analyzed in entire countries or parts thereof). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to  the web version of this article.)
10 J.-P. Empana et al. / Resuscitation 124 (2018) 7–13
Table 1
The ESCAPE-NET consortium.
Name Country Role
Academic partners
Academic Medical Center (Project
Coordinator Dr. Tan)
The Netherlands Cohort, clinical studies
University of Copenhagen Denmark Cohort, clinical studies
Université Paris Descartes France Cohort, clinical studies
University of Pavia and IRCCS Istituto
Auxologico Italiano
Italy Cohort, clinical studies
VU  University Medical Center The Netherlands Cohort, clinical studies
Karolinska Institute Sweden Cohort, clinical studies
Emergency Medical Services of the
Hradec Kralove Region
Czech Republic Cohort, clinical studies
Istituto di Ricerche Farmacologiche
“Mario Negri”
Italy Cohort, clinical studies
Helmholtz Zentrum München Germany Genotyping
Fundació Institut Mar  d’Investigacions
Mèdiques
Spain Pharmacological analysis
European scientiﬁc societies/associations for SCA research
European Society of Cardiology (ESC),
representing the European Heart
Rhythm Association (EHRA)
France Dissemination, Education, Implementation
European Resuscitation Council (ERC) Belgium Dissemination, Education, Implementation
Small  and medium sized enterprises
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atient cohorts
ESCAPE-NET contains 11 deep-phenotyped SCA case cohorts
otaling 85,790 SCA cases (Table 2) and 5 deep-phenotyped obser-
ational prospective population cohorts totaling >50,000 subjects
Table 3). The latter cohorts are of high added importance since they
ontain detailed information before SCA has occurred, and will be
sed to study the determinants of SCA occurrence. ESCAPE-NET
ill also aim for enrichment of the data by linking them to (pub-
icly available) registries, for instance, Statistics Netherlands and
tatistics Denmark for collection of socio-economic data.
ata harmonization and integration
A primary step is to make a list of variables which are com-
on  to all cohorts based on clinical relevance and availability. Two
nterconnected data harmonization committees have been created,
ne for the SCA cohorts and another for the observational prospec-
ive population cohorts. As much as possible, the same deﬁnitions
or exposures/outcomes that were common to each type of cohort
ere used. Linkage with national claim databases will permit to
etrieve trajectories of exposures to different drugs, taking into
ccount duration and dose of exposure to the drug. Furthermore,
iven the large number of SCA cases, class and drug effects can be
valuated.
utcome data
The main outcome is SCA in patients with documentation of
F, and sudden cardiac death (SCD) in patients without VF docu-
entation. The same standardized deﬁnition for SCD and the same
ariables required to deﬁne it have been adopted in the population
nd clinical cohorts:Deﬁnite sudden cardiac death:  A sudden, natural unexpected
death with established time frame from change in cardiovascular
status to death:Health Economics analysis
Bioinformatics platform
Project management
© Witnessed cases: acute change in cardiovascular status with
time to death <1 h
© Unwitnessed cases: a person last seen alive and functioning
normally <24 h before being found dead.
• Probable sudden cardiac death:  Death in a person with cause of
death (derived from, e.g., autopsy reports, the National Causes
of Death Register, hospital records) likely to be sudden death in
an otherwise healthy person free of any chronic and/or severe
diseases.
Moreover, information on vital status and related causes of
deaths will be obtained by the national registry of the causes of
death of each participating country. The neurologic status at hos-
pital discharge will be obtained using the Cerebral Performance
category (CPC) [34]. Long-term follow-up is not yet funded, but
may  be envisaged pending on future funding.
Power
Estimating the required power in a large scale multinational
project with various aims and main exposures is a challenging issue.
Based on prior experience from consortium members, a minimum
of 100 incident cases per cohort is a pre-requisite to conduct multi-
variate analysis. As an example, with 118 incident SCA cases among
7773 participants, the Paris Prospective Study I was able to retrieve
speciﬁc risk factors for SCA in the population, including the discov-
ery that family history of SCA has a strong inﬂuence on the risk of
SCA in the offspring. (3) Hence, with a total of 85,790 SCA cases, the
ESCAPE-NET consortium is expected to be sufﬁciently powered to
address its main objectives.
DNA collection and analysis
DNA collection methods vary between cohorts. The most chal-
lenging is DNA collection of non-surviving SCA victims, because
postmortem collection of biosamples solely for the sake of research
is not allowed in some countries, e.g., the Netherlands; here
(ARREST), the solution is to collect biosamples obtained for the
J.-P. Empana et al. / Resuscitation 124 (2018) 7–13 11
Table  2
SCA cohorts.
Name Partner Country Cause of SCA SCA cases (N) DNA samples (N)
ARREST [21] AMC  NL all-cause 13786 4473
AGNES [19] AMC NL ﬁrst myocardial infarction 1023 1023
Cartagene [19] UP FR all-cause 2332 1518
Paris  Sudden Death Expertise [22] UP FR all-cause 10093 none
Danish Cardiac Arrest registry [1] REGIONH DK all-cause 47000 6000
SCDY  in Denmark [23] REGIONH DK all-cause 1463 140
GEVAMI [24] REGIONH DK ﬁrst myocardial infarction 1100 1100
Predestination [25] UPAV, AUXO IT ﬁrst myocardial infarction 341 341
Stockholm Region [26] KI SE all-cause 6100 none
EMS  Hradec Kralove Region [27] EMS  CZ all-cause 1779 none
RIAC  [28] IRFMN IT all-cause 773 none
Total  85790 14595
Table 3
Observational prospective population cohorts.
Name Partner Country Population type Persons followed (N) SCA cases (N) DNA
Paris Prospective Study 3 [29] UP FR general population 10157 130 3800
Copenhagen City Heart Study [30] REGIONH DK general population 24000 2000 none
Hoorn studies [31] VUMC NL general population 5237 190 3953
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Total  
ake of patient care which are left over and would otherwise
e discarded (blood samples, endotracheal tubes). To maximize
tandardization, all DNA analyses are conducted by one partner
Helmholtz Zentrum München) using the Illumina Global Screen-
ng Array which contains >770,000 SNPs, and deep-sequenced
atasets as reference panels for imputation, e.g., Haplotype Ref-
rence Consortium. Hence, a database of an estimated >9 million
ariants (3,6 times larger than the number of variants in the most
ecent genome-wide association study on SCA [20]) in >15,000 SCA
amples will be available for genetic association. This will allow
 genome-wide assessment of common genetic variants and an
ssessment of the role of rare variants within genes from selected
athways based on a hypothesized (patho)physiological role. The
SCAPE-NET consortium has the added ability to study the mag-
itude of the functional effect in the pipeline of functional and
ranslational studies conducted at the Laboratory of Experimental
ardiology of AMC, of which the Project Coordinator is part [35].
etwork analysis of the ﬁndings from the genetic studies will be
onducted with the aim of discovering proteins and pathways that
ay  provide the basis for novel prevention and treatment strategies
nd/or drug design.
nvestigating ﬁrst-response treatment for SCA and survival across
urope
The ESCAPE-NET consortium has the opportunity to perform a
arge systematic study aimed to compare the efﬁcacy of the dif-
erent treatment protocols across Europe. As an innovation, the
ontribution of ﬁrst-response treatment strategy will be estimated
aking into account inherited, acquired, socio-economic, and envi-
onmental factors. Several options are available to compare the
fﬁcacy of treatment strategies. One is to relate change in sur-
ival rate to change in resuscitation strategy. Another is to compare
urvival rates between study sites and see whether differences
elate to different resuscitation strategies between those sites.
nterestingly, survival comparisons before and after the ERC 2015
nternational Guidelines for the treatment of an SCA victim could
e undertaken. Finally, recent studies have led to the hypothesis
hat detailed analysis of VF waveforms over time such as ampli-
ude spectrum area, could provide prognostic information for both
he success of deﬁbrillation and clinical outcomes [36]. Accordingly, mellitus 6666 to be determined 6666
 mellitus 7000 240 6000
53060 2560 20419
under the umbrella of ESCAPE-NET, the «AMplitude Spectrum Area
to guide deﬁbrillation during cardiopulmonary resuscitation in
out-of-hospital cardiac arrest patients»–AMSA trial, a multicenter
randomized clinical trial, will be conducted to test this hypothesis.
Health economics analysis
The effect of implementation of the use of most-effective ﬁrst-
response treatment will be assessed. A comprehensive health
economic model is used for this purpose, and sensitivity analy-
ses are used to propagate uncertainty in the input data to the
model outcomes. Several relevant scenario analyses are performed
to further enhance the understanding of the relation between char-
acteristics of the most-effective ﬁrst response treatment and its
health economic impact. To gain insight into the costs and beneﬁts
of ﬁrst-response treatment programs, the costs of the program itself
will be assessed (e.g., development of app-system, implementation
schemes), but also potential savings in health care costs. In-hospital
health care parameters will be compared (i.e., SCAs involving lay
rescuers vs. emergency medical services only, per type of program),
analyzing costs of hospital transport, duration and cost of admis-
sion in hospital, diagnostics and interventions [37]. Costs will be
measured from the perspective of society and extrapolated after
the ﬁrst year.
Building risk prediction models for SCA occurrence and for SCA
survival
The ESCAPE-NET consortium will develop and validate risk
scores predicting occurrence of SCA and survival after SCA, using
the same methodological approach. The ﬁrst step will be to identify
signiﬁcant predictors using Cox proportional hazard models. Given
the number of potential candidates and the variety of dimensions
(including clinical variables, socio-economic factors, drugs), we
will ﬁrst identify predictors within each dimension and then enter
them into a single multivariate model. As usual, 2 by 2 interactions
between the retained variables will be investigated. Second, we
will evaluate the performances of the model assessing (a) calibra-
tion (b) the discrimination of the model using the Harell’s C index
adapted to censored data. Reclassiﬁcation analysis (Net Reclassiﬁ-
cation index, Integrated Discrimination Improvement) could also
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e used in case we wish to assess the added value of a speciﬁc
ovariate (e.g., depression) above a set of more traditional covari-
tes [38]. For validation, several options are available: (1) within
SCAPE-NET, develop the model in a derivation set (i.e., in 2 cohorts
ombined) and validate it in the remaining cohorts (validation set);
2) use all ESCAPE-NET cohorts to derive the model and perform
xternal validation through international collaborations pending
n the availability of the covariates in these validation cohorts (i.e.,
he case for genetic data); (3) use all ESCAPE-NET cohorts to derive
nd validate the model (internal validation) using cross-validation
ethods and penalization procedures to correct for over-optimism.
overnance and collaborations
An Executive Committee has been created along with a Collabo-
ation Policy document, which includes sections on quality control,
ublication rules, and ways to solve possible conﬂicts. One section
eals with collaborations within and outside of the consortium and
roposals for joint research from inside and outside of the consor-
ium. At present, collaborations with some US cohorts are already in
lace and will be continued, including the Physicians Health study,
he Nurses Health study, the Oregon registry, and the CHARGE con-
ortium [20].
iscussion
The aim of the ESCAPE-NET project is to maximize the exploita-
ion of major deep-phenotyped European SCA cohorts by bringing
hem together in one joint database of 85,790 SCA cases. This will
enerate the power necessary to unravel the complex causes of
CA with the strategy of a multi-scale approach, ranging from
enomics to the socio-economic environment of each individual
n the community. This will form the foundation of a personalized
isk score, and the development of effective individualized pre-
ention and treatment strategies. As treatment of SCA (particularly
rst-response treatment) is different between European countries,
ombining the large cohorts that are present across Europe addi-
ionally creates the opportunity to evaluate and compare treatment
trategies.
Large nationwide registries such as in Japan [39] or binational
USA and Canada) registries such as the EPISTRY registry [40] exist.
lthough these may  already investigate heterogenity of risk fac-
ors, clinical management and prognosis, we believe that with its
ultinational design, these aspects may  be expanded and reﬁned
ithin ESCAPE-NET. In addition and beyond these Japanese and
orth-American registries, biosamples are available in ESCAPE-NET
nd genotyping is already funded (genome-wide association stud-
es) and planned (whole-exome sequencing). Still, the availability
f these registries outside Europe provides ESCAPE-NET excellent
pportunities for collaborations and international comparisons.
At the European level, the European Registry of Cardiac Arrest
roject (EuReCa) provides a detailed overview on epidemiology,
reatment and outcome of patients suffering out-of-hospital SCA
n 27 European countries. EuReCa One was a 1-month survey of
0,000 such cases [16], while EuReCa Two, which has commenced
n 1 October 2017, will be a 3-months survey with a special focus
n lay resuscitation. Similar to the Japanese and North-American
egistries, biosamples are not available in the EuReCa surveys. Like-
ise, these registries are not designed with the speciﬁc aim of
valuating risk factors for occurrence of SCA as opposed to the
eeply phenotyped cohorts of ESCAPE-NET.tion 124 (2018) 7–13
Limitations
We  recognize the following limitations. Firstly, despite the har-
monization of the variables and outcome deﬁnitions, some degree
of heterogenity will remain. As a corollary, some important vari-
ables are not available in all cohorts. For these cohorts, subgroup
analysis only can be conducted. Secondly, in these observational
cohorts, causality can be suggested but not established. Thirdly,
despite the size of the consortium, not all European countries
are represented so that the picture may  not be representative
for the entire European population. However, ESCAPE-NET is a
dynamic project with the speciﬁc aim of reaching out and inviting
other cohorts/registries to join or collaborate with the consor-
tium. Finally, despite the already wide spectrum of areas covered
by ESCAPE-NET, additional and important areas deserve future
consideration. For instance, omics analysis could be conducted
in subgroups pending on future obtained grants. In particular,
the availability of large biobanks in all observational prospective
population cohorts offers the possibility to identify circulating
biomarkers for the occurrence of SCA. Also, long-term follow-up
of neurologic/functional status is an important aspect to study.
Conclusion
ESCAPE-NET has a broad scope and will make major contribu-
tions to understanding SCA on all levels. This will not only impact
direct patient care (development of individualized novel preventive
and therapeutic strategies for SCA), but also the organization of out-
of-hospital and in-hospital health care in Europe. Moreover, it will
have public health implications, and establish a lasting framework
for future basic and clinical scientiﬁc investigations.
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